Sirolimus-eluting stents: A review of experimental and clinical findings

Zeitschrift fur Kardiologie

Volumn 91, Issue SUPPL. 3, 2002, Pages 49-57

  Toutouzas, Konstantinos ^a   Di Mario, Carlo ^a   Falotico, Robert ^b   Takagi, Takuro ^a   Stankovic, Goran ^a   Albiero, Remo ^a   Corvaja, Nicola ^a   Colombo, Antonio ^a  

^a EMO GVM CENTRO CUORE COLUMBUS   (Italy)

^b Department of Medical Affairs and Health Ecomomics Worldwide   (United States)

Author keywords

FIM; Rapamycin; RAVEL; Restenosis; Sirolimus; Stent

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOPEPTIN; CILOSTAZOL; CLOPIDOGREL; DACTINOMYCIN; DEXAMETHASONE; MACROLIDE; PACLITAXEL; RAPAMYCIN; TICLOPIDINE; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT;

ANGIOGRAPHY; ANIMAL EXPERIMENT; ARTERY INTIMA PROLIFERATION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY STENT; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RELEASE; HUMAN; INTRAVASCULAR ULTRASOUND; MAJOR CLINICAL STUDY; NONHUMAN; PHARMACOKINETICS; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; TREATMENT INDICATION; TREATMENT OUTCOME; ANGINA PECTORIS; ANGIOCARDIOGRAPHY; ANIMAL; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; DISEASE MODEL; DRUG DELIVERY SYSTEM; ENDOSCOPIC ECHOGRAPHY; FOLLOW UP; INTRAMUSCULAR DRUG ADMINISTRATION; MULTICENTER STUDY; RAT; REVIEW; STENT; SWINE; THROMBOSIS; TIME; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGINA PECTORIS; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMAL; ASPIRIN; COMPARATIVE STUDY; CORONARY ANGIOGRAPHY; CORONARY DISEASE; CORONARY RESTENOSIS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; FOLLOW-UP STUDIES; HUMAN; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS, INTRAMUSCULAR; MULTICENTER STUDIES; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS; RATS; SIROLIMUS; STENTS; SWINE; THROMBOSIS; TICLOPIDINE; TIME FACTORS; ULTRASONOGRAPHY, INTERVENTIONAL; ANIMALS; HUMANS;

EID: 0036320361     PISSN: 03005860     EISSN: None     Source Type: Journal    
DOI: 10.1007/s392-002-8371-x     Document Type: Conference Paper

References (34)

1. The clinical effectiveness of paclitaxel coated coronary stents for the reduction of restenosis in the ASPECT trial
2. Short- and intermediate-term results of(32)P radioactive beta-emitting stent implantation in patients with coronary artery disease: The Milan Dose-Response Study
3. Edge restenosis after implantation of high activity (32)P radioactive beta-emitting stents
4. Neointimal formation after balloon-induced vascular injury in Yucatan minipigs is reduced by oral rapamycin
5. Stent based sirolimus delivery reduces neointimal proliferation in a porcine coronary model of restenosis
6. Late coronary occlusion after intracoronary brachytherapy
7. Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle
8. Local drug delivery to inhibit coronary artery restenosis. Data from the ELUTES (evaluation of paclitaxel eluting stent) clinical trial
9. Treatment with rapamycin and mycophenolic acid reduces arterial intimal thickening produced by mechanical injury and allows endothelial replacement
10. TAXUS I: Prospective, randomized, double-blind comparison of NIR-X stents coated with paclitaxel in a polymer carrier in de novo coronary lesions with uncoated controls
11. Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast
12. Chronic arterial responses to stent implantation: A serial intravascular ultrasound analysis of Palmaz-Schatz stents in native coronary arteries
13. Prevention of restenosis by a new drug eluting stent: An intravascular ultrasound substudy of the SCORE trial
14. Stent-based delivery of sirolimus for the prevention of restenosis
15. Localized intracoronary gamma-radiation therapy to inhibit the recurrence of restenosis after stenting
16. Attacking heart disease with novel molecular tools
17. Bench to bedside: The development of rapamycin and its application to stent restenosis
18. In-stent restenosis: The Washington Hospital Center experience
19. The clinical effectiveness of paclitaxel coated coronary stents for the reduction of restenosis in the ASPECT trial
20. Renal transplantation, past, present and future
21. Rapamycin reverses chronic graft vascular disease in a novel cardiac allograft model
22. Coronary restenosis elimination with a sirolimus eluting stent. First European human experience with 6-month angiographic and intravascular ultrasound follow-up
23. Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization
24. Rapamycin (sirolimus, rapamune)
25. Rapamune (Sirolimus, rapamycin): An overview and mechanism of action
26. Comparison of coronary-artery bypass surgery and stenting for the treatment of multivessel disease
27. Sirolimus-coated stents for the treatment of in-stent restenosis: The first in-man experience
28. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: A quantitative coronary angiography and three-dimensional untravascular ultrasound study
29. The RAVEL study: A randomized study with the sirolimus coated BX velocity balloon expandable stent in the treatment of patients with de novo coronary artery lesions
30. Role for p27 (Kip1) in vascular smooth muscle cell migration
31. Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model
32. Catheter based radiotherapy to inhibit restenosis after coronary stenting
33. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle
34. Prolonged antiplatelet therapy to prevent late thrombosis after intracoronary gamma radiation in patients with in-stent restenosis: Washington Radiation for In-Stent Restenosis Trial plus 6 months of clopidogrel (WRIST PLUS)